Physician profile
Lester Greer
NPI 1801058375
$404.73
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $94.07 · 2022: $24.80 · 2023: $236 · 2024: $49.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $285.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $94.07 | 2020 | |
| Teleflex LLC | $30.41 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $24.80 | 2022 | |
| Morphosys, US INC. | $24.61 | 2023 | Monjuvi |
| Genzyme Corporation | $24.49 | 2023 | |
| Janssen Biotech, INC. | $23.37 | 2023 | Imbruvica |
| Exelixis INC. | $23.29 | 2023 | Cabometyx |
| Incyte Corporation | $20.41 | 2023 | Jakafi |
| Amgen INC. | $19.14 | 2023 | Blincyto, Kyprolis |
| Boston Scientific Corporation | $19.04 | 2024 | |
| Lilly USA, LLC | $18.47 | 2023 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $18.16 | 2023 | Keytruda, Lynparza |
| Acrotech Biopharma INC. | $17.07 | 2023 | Beleodaq |
| Eisai INC. | $16.20 | 2023 | |
| Stemline Therapeutics INC. | $15.66 | 2023 | Orserdu |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $15.54 | 2023 | Adcetris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lester Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.